Condiciones de salud que corteza de pino puede ayudar a apoyar.
Pycnogenol (pine bark extract) has been tested in randomized, double-blind, placebo-controlled (RDP) trials for allergic rhinitis and asthma. It reduces nasal and ocular symptoms in hay fever patients and lowers leukotriene levels, an inflammatory mediator involved in both asthma and hay fever. Multiple RDP trials support respiratory allergy benefit.
Pine bark extract (most studied as Pycnogenol®, from Pinus pinaster) has robust clinical evidence supporting antioxidant defense. Its primary constituents—procyanidins and phenolic acids—scavenge reactive oxygen and nitrogen species, suppress peroxide formation, and upregulate intracellular antioxidant enzymes including glutathione. Multiple randomized, double-blind, placebo-controlled trials in humans have documented measurable reductions in oxidative stress biomarkers. Evidence quality is moderate-to-good, though some methodological limitations persist across the broader literature.
Pine bark extract (particularly Pycnogenol/French maritime pine bark) has multiple clinical trials supporting improved endothelial function, reduced blood pressure, and decreased arterial oxidative stress. A 2012 meta-analysis (Phytotherapy Research) confirmed significant BP reductions. Pine bark proanthocyanidins enhance NO production and protect vascular endothelium from oxidative damage.
Multiple RCTs show Pycnogenol reduces pain, stiffness, and analgesic use in knee osteoarthritis. The 2018 PubMed review confirmed restored mobility in seniors with osteoarthritis. Mechanistically, Pycnogenol inhibits cartilage-degrading enzymes and reaches synovial fluid after oral administration.
Pine bark extract (Pycnogenol), rich in proanthocyanidins, has been evaluated in RCTs for asthma. A double-blind RCT in 60 children aged 6–18 with mild-to-moderate asthma found Pycnogenol supplementation significantly improved lung function and asthma symptoms compared to placebo. A follow-up adult trial confirmed adjunct benefit vs. inhaled corticosteroid alone.
Clinical trials show Pycnogenol improves physical fitness metrics and endurance in recreational athletes and triathletes. In two-part controlled studies, 100–150 mg/day over 4–8 weeks significantly improved run times, push-up and sit-up counts, and triathlon completion times. Mechanisms include antioxidant control of exercise-induced oxidative stress and improved microcirculation.
Pine Bark extract (Pycnogenol®, from Pinus pinaster) has been evaluated in RCTs for pediatric ADHD, with a 2006 double-blind RCT (n=61 children, 4 weeks, 1 mg/kg/day) showing significant reductions in hyperactivity and inattention versus placebo. A 2022 RCT confirmed significant ADHD-RS improvements over placebo at 10 weeks.
RCTs demonstrate Pycnogenol inhibits platelet aggregation and prevents venous thrombosis. The LONFLIT-FLITE randomized controlled trial showed prevention of venous thrombosis in long-haul flights. Pycnogenol's antithrombotic properties are based on inhibition of platelet aggregation and reduction of thromboxane.
Pine bark extract (the base of Pycnogenol) contains oligomeric procyanidins and phenolic acids shown to reduce blood pressure in RCTs via ACE inhibition and nitric oxide-mediated vasodilation. Multiple meta-analyses of pine bark extract (primarily Pycnogenol) trials support modest antihypertensive effects.
Multiple RCTs demonstrate Pycnogenol lowers fasting plasma glucose and HbA1c in type 2 diabetes patients as an adjunct to standard therapy. A meta-analysis confirmed significant reductions in fasting blood glucose, HbA1c, and LDL-cholesterol. Mechanism involves improved endothelial function and insulin sensitivity.
Pycnogenol reduces markers of cartilage degradation such as MMP-3, MMP-13, and IL-1β in patients with severe osteoarthritis. Its polyphenolic constituents distribute into synovial fluid. Multiple RCTs show reduced pain, stiffness, and analgesic use in osteoarthritis patients.
Meta-analyses and RCTs show Pycnogenol significantly reduces LDL-cholesterol and raises HDL-cholesterol. A 200-woman peri-menopausal RCT found 9.9% LDL reduction and 4.6% HDL increase after 6 months of 200 mg/day. The meta-analysis confirmed LDL reduction of WMD −7.12 mg/dl and HDL increase of +3.27 mg/dl.
Pycnogenol inhibits key inflammatory pathways including NF-κB, COX-2, 5-LOX, and TNF-α, and lowers circulating CRP in clinical studies. It has been validated as an anti-inflammatory in multiple RCTs spanning cardiovascular, joint, periodontal, and metabolic conditions. The anti-inflammatory mechanism underpins most of its documented clinical benefits.
Pine bark extract (primarily Pycnogenol® from French maritime pine) is among the most studied plant extracts for circulation, with 35+ years of research demonstrating improved blood flow, strengthened venous walls, reduced oedema, and improved microcirculation in chronic venous insufficiency. A key RCT (n=86 severe CVI patients) showed pine bark extract outperformed diosmin-hesperidin for reducing capillary filtration, oedema, and skin changes, and improving tissue oxygenation.
Multiple RCTs and a PMC systematic review confirm Pycnogenol improves cognitive function in older adults, including spatial memory, learning, and daily capabilities. It has been tested specifically in elderly populations and individuals with mild cognitive dysfunction. Antioxidant neuroprotection and cerebrovascular improvements are key mechanisms.
Pine bark extract (Pycnogenol) contains proanthocyanidins that increase intercellular vitamin C levels, inhibit collagen destruction by blocking collagenase and elastase, and reduce inflammatory damage to connective tissue. Multiple clinical trials show benefits for joint OA symptoms and skin connective tissue elasticity. It is one of the better-evidenced plant extracts for connective tissue protection.
RCT evidence shows Pycnogenol supplementation improves skin hydration and elasticity, particularly in women with dry skin. Six weeks of supplementation increased hydration by 21% in dry-skin subjects vs. 8% in normal-skin subjects. Mechanisms include upregulation of hyaluronic acid synthase and collagen type I synthesis.
A clinical study published in the Journal of Reproductive Medicine showed Pycnogenol reduced endometriosis symptoms by 33%. A subsequent study found 90% of patients became pain-free. Pycnogenol does not exert estrogen-like activity, which is important for safety in this estrogen-sensitive condition.
Pine bark extract (Pycnogenol, from Pinus pinaster) has been evaluated in clinical studies for erectile dysfunction, primarily in combination with L-arginine. Two studies testing 120 mg/day of Pycnogenol as a sole intervention reported improvements in erectile function. A 2023 meta-analysis (Frontiers Endocrinology) of the Pycnogenol–L-arginine combination confirmed significant IIEF improvements.
Clinical studies show Pycnogenol, alone or combined with L-arginine (as Prelox), improves sperm morphology, motility, and count in subfertile men. The percentage of morphologically normal spermatozoa increased by 99% in one study. Mechanisms involve antioxidant protection of spermatozoa and enhanced nitric oxide signaling.
Pycnogenol (French maritime pine bark extract, 1 mg/kg/day for 4 weeks) produced significant improvements in hyperactivity, inattention, and visual-motor coordination over placebo in a double-blind RCT in children with ADHD. A 2024 network meta-analysis of 48 pediatric ADHD studies (n=3,650) ranked pycnogenol (SUCRA 0.36) among the top two most effective nutrient/antioxidant interventions for improving attention.
RCTs show Pycnogenol improves attention and concentration in children with ADHD and in older adults with mild cognitive dysfunction. A 2022 RCT compared Pycnogenol to methylphenidate in 88 children over 10 weeks, finding comparable improvements in ADHD symptoms with significantly fewer adverse effects. Catecholamine modulation and antioxidant neuroprotection are the proposed mechanisms.
Pine bark extract (Pycnogenol®, from Pinus pinaster) contains oligomeric proanthocyanidins with potent antioxidant and vascular-protective effects in the retina. Small clinical studies have shown it reduces retinal leakage and improves visual acuity in early diabetic retinopathy and reduces intraocular pressure when combined with bilberry. It protects retinal cells from oxidative damage.
A 2025 RCT (n=91) demonstrated Pycnogenol 100 mg twice daily significantly reduced salivary MMP-8 and serum IL-6 vs. placebo during non-surgical periodontal therapy. Animal studies show inhibition of alveolar bone resorption in periodontitis models. Evidence supports Pycnogenol as an adjunct to mechanical plaque removal.
Pine bark extract (particularly Pycnogenol from French maritime pine) is rich in procyanidins and phenolic acids that stimulate dermal papilla cell proliferation, improve scalp microcirculation, and provide antioxidant protection. A 6-month RCT found pine bark extract supplementation significantly increased hair density in women with thinning hair.
Pycnogenol has been reviewed as a pleiotropic agent supporting healthy aging across cardiovascular, cognitive, musculoskeletal, sexual, and menopausal domains in controlled clinical trials. A 2018 PubMed review summarized diverse positive effects on aging-relevant outcomes from double-blind, placebo-controlled studies. Its antioxidant, anti-inflammatory, and endothelial effects underpin these broad benefits.
Pine bark extract (Pycnogenol) improves cochlear blood flow and microcirculation, and has been evaluated in small clinical trials for tinnitus and sudden sensorineural hearing loss. It enhances endothelial nitric oxide production, improving inner-ear vasculature. A controlled study found pine bark extract improved tinnitus and hearing in patients with Meniere's disease.
Multiple RCTs demonstrate Pycnogenol lowers blood pressure, reduces LDL cholesterol, improves endothelial function, inhibits platelet aggregation, and slows atherosclerosis progression. A meta-analysis confirmed significant reductions in systolic and diastolic blood pressure and LDL-cholesterol. These cardiovascular benefits are among the best-documented effects of the extract.
Clinical studies including RCTs have documented Pycnogenol's efficacy in reducing acute hemorrhoidal episodes and postpartum hemorrhoid symptoms. The mechanism relates to venous tone improvement, anti-inflammatory action, and strengthening of capillary walls. Studies by Belcaro et al. are cited as primary evidence.
Pine bark extract (Pycnogenol, from Pinus pinaster) contains oligomeric proanthocyanidins that inhibit tyrosinase, reduce UV-induced hyperpigmentation, and have been included in clinical combination formulations for melasma. It is listed among antioxidants reviewed for melasma management.
Meta-analyses and RCTs confirm Pycnogenol significantly improves fasting blood glucose, HbA1c, and insulin-related cardiometabolic parameters in type 2 diabetic and metabolic syndrome patients. Improvements in endothelial function and glucose metabolism have been validated in double-blind clinical trials.
Pine bark extract (Pycnogenol, 150 mg/day) was studied in a published open pilot registry trial (Ledda et al., Evid Based Complement Alternat Med 2021; PMID 34257695) in 64 subjects with recurrent UTI or IC; compared with cranberry extract and standard management, Pycnogenol produced a 62% reduction in UTI/IC episode rate and 91% elimination of symptoms over 2 months.
Pycnogenol combined with L-arginine (as Prelox) significantly improves erectile function in men with erectile dysfunction in RCTs, with IIEF-5 scores improving from moderate ED to normal range. Pycnogenol alone also shows benefit in some pilot studies. Mechanism involves enhanced eNOS activity and increased nitric oxide availability for penile vasodilation.
Pine bark extract (Pycnogenol) is standardized for oligomeric proanthocyanidins and provides potent antioxidant and microcirculatory benefits. A clinical study found that Pycnogenol supplementation improved retinal blood circulation and visual acuity in AMD patients with early retinal damage, and it is cited by authoritative natural eye care resources as a complement to lutein/zeaxanthin in AMD management. Preclinical studies support its anti-VEGF and anti-inflammatory actions in retinal tissue.
Multiple RCTs and a 2019 PMC review confirm Pycnogenol improves memory, particularly spatial memory, in elderly individuals and those with mild cognitive impairment. Human clinical trials show improvements in memory, learning, and daily cognitive capabilities. Antioxidant neuroprotection and vascular mechanisms are implicated.
Two RDP trials in peri-menopausal women demonstrate Pycnogenol significantly reduces menopausal symptoms including hot flashes, night sweats, mood swings, vaginal dryness, and sleep disturbance. A 200-woman RCT using the Women's Health Questionnaire showed significant improvement vs. placebo at 6 months. Benefit appears independent of hormonal activity.
A multicenter RCT and an open clinical trial both demonstrate Pycnogenol significantly reduces dysmenorrhea pain and analgesic medication use. The Journal of Reproductive Medicine (2008) RCT showed reduced pain and lower analgesic requirement. Mechanism involves spasmolytic action of phenolic acids and anti-inflammatory inhibition of prostaglandins.
Systematic reviews confirm Pycnogenol improves multiple components of metabolic syndrome including blood glucose, blood pressure, waist circumference, and lipid profile. A Wiley review and meta-analysis support improvements in endothelial and renal function in metabolic syndrome patients. It is considered appropriate for targeting the multifaceted pathophysiology of this condition.
Early clinical research suggests that pine bark extract (Enzogenol) combined with vitamins E and C for 3 months reduces the severity and likelihood of migraine. The evidence is preliminary and based on a small study. Anti-inflammatory and vascular effects are proposed mechanisms.
Clinical trials demonstrate Pycnogenol reduces exercise-induced muscle cramps, soreness, and oxidative stress markers, and accelerates metabolic recovery post-exercise. A triathlete RCT showed significantly reduced cramps and post-exercise pain, and faster recovery of plasma free radical levels. Mechanism involves antioxidant attenuation of oxidative stress.
Pine bark extract (standardized as Pycnogenol from Pinus pinaster) stimulates eNOS transcription and activity, scavenges superoxide radicals that degrade NO, and has human clinical evidence for improved endothelial function and blood pressure, with documented synergy with L-arginine for NO-mediated improvements in erectile dysfunction.
Four separate RDP trials confirm Pycnogenol enhances sport endurance and performance. An RDP crossover study showed significantly increased endurance run time at 85% VO2 max after 30 days of 200 mg/day. Triathlete and recreational athlete data show improved times and sustained energy output. Improved microvascular oxygen delivery is the mechanistic basis.
Clinical evidence supports Pycnogenol for relief of premenstrual symptoms including abdominal pain. A review of clinical pharmacology noted PYC relieves premenstrual symptoms including abdominal pain via spasmolytic action of phenolic acids. The menstrual cramp RCTs also enrolled women with PMS-type symptoms.
Clinical studies including a controlled trial show Pycnogenol reduces urinary symptoms of BPH, including nocturia frequency and urinary intermittency, more effectively than controls. The 2018 PubMed review confirmed BPH urinary symptom reduction. Mechanism may involve anti-inflammatory effects on prostatic tissue.
A clinical study published in Minerva Cardioangiologica (2019) demonstrated Pycnogenol improves microcirculation and reduces main symptoms of mild, primary Raynaud syndrome. The improvement in peripheral vascular function aligns with Pycnogenol's established mechanisms of endothelial nitric oxide enhancement and platelet aggregation inhibition.
Pycnogenol, the patented extract of French maritime pine bark, was tested in two RCTs for seasonal allergic rhinitis and found to significantly reduce nasal and ocular symptoms when started 5+ weeks before pollen season. NCCIH names Pycnogenol (pine bark) among studied approaches for allergic rhinitis.
Pine bark extract (the source of Pycnogenol and related proanthocyanidin-rich preparations) has clinical RCT evidence for skin aging. Oral supplementation at 75 mg/day for 12 weeks (randomized, placebo-controlled) significantly improved skin elasticity and hydration in postmenopausal women. Pine bark proanthocyanidins inhibit collagenase and elastase, stimulate collagen synthesis, and provide systemic photoprotection.
Pine bark extract (source of Pycnogenol) contains procyanidins and phenolic acids that inhibit collagen-degrading matrix metalloproteinases and increase collagen type I gene expression in human skin. A 12-week RCT in 20 postmenopausal women showed improved skin elasticity and hydration with biopsies confirming increased collagen type I and hyaluronic acid synthase gene expression.
Pine bark extract (primarily Pycnogenol from French maritime pine) is one of the most clinically studied natural products specifically for spider veins and chronic venous insufficiency. Multiple RCTs show reduction in spider vein clusters, improved post-pregnancy vein health, and superior edema reduction compared to diosmin/hesperidin. Over 25 vein-specific studies have been conducted.
Pine bark extract (primarily as Pycnogenol from Pinus pinaster) contains proanthocyanidins with documented UV photoprotective activity. Clinical evidence demonstrates it reduces UV-induced hyperpigmentation and melasma, improves skin barrier function, and provides oral photoprotection. Reviews confirm photoprotection as a primary evidence-based use of pine bark extract supplements.
A clinical study showed that improvement of cochlear microcirculation with Pycnogenol terminated tinnitus and Ménière's disease in 87% of patients vs. 35% in controls. The mechanism involves improved microvascular blood flow to the inner ear. Evidence is pilot-level with a strong effect size.
Pine bark extract (standardized as Pycnogenol from French maritime pine, Pinus pinaster) has clinical evidence from multiple RCTs for reducing CVI symptoms and varicose vein-related edema. In a 98-subject RCT, 150 mg/day for 8 weeks significantly reduced ankle swelling, resting skin flux, and CVI symptom scores, outperforming diosmin-hesperidin. It has been shown to improve venous tone in varicose vein segments and slow progression of varicose veins. Multiple clinical studies support 100–150 mg/day for CVI.
Clinical studies show Pycnogenol reduces peripheral edema and leg swelling, including in pregnant women, long-haul flight passengers, and patients with chronic venous insufficiency. Its vasoprotective and anti-inflammatory actions reduce capillary permeability and venous stasis. Controlled studies documented reduction of edema in hypertensive patients and travelers.
Traditional medicinal use of pine bark for wound healing dates to Hippocrates (~400 BC) and Native American practices. Animal and in vitro studies show Pycnogenol accelerates wound healing and reduces scar formation. Limited human study data exist; clinical applications include venous ulcer management.
Volver